The Use of Prostate Specific Antigen, Clinical Stage and Gleason Score to Predict Pathological Stage in Men with Localized Prostate Cancer

Morton, 1991, Cancer control following anatomical radical prostatectomy: an interim report, J. Urol., 145, 1197, 10.1016/S0022-5347(17)38574-9

Carter, 1988, Prostate cancer: the magnitude of the problem in the United States, 1

Rifkin, 1990, Comparison of magnetic resonance imaging and ultrasound in staging early prostate cancer. Results of a multi-institutional cooperative trial, New Engl. J. Med., 323, 621, 10.1056/NEJM199009063231001

Stamey, 1987, Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate, New Engl. J. Med., 317, 909, 10.1056/NEJM198710083171501

Partin, 1990, Prostate specific antigen in the staging of localized prostate cancer: Influence of tumor differentiation, tumor volume and benign hyperplasia, J. Urol., 143, 747, 10.1016/S0022-5347(17)40079-6

Jewett, 1968, The palpable nodule of prostate cancer: results 15 years after radical excision, J.A.M.A., 203, 403, 10.1001/jama.1968.03140060027007

Kramer, 1980, Experience with Gleason histopathologic grading in prostatic cancer, J. Urol., 124, 223, 10.1016/S0022-5347(17)55381-1

Oesterling, 1987, Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathological stage in 275 patients with clinically localized adenocarcinoma of the prostate, J. Urol., 138, 92, 10.1016/S0022-5347(17)43003-5